Clinical trials evaluating GLP-1 receptor agonists, such as the LEADER trial for liraglutide and the SUSTAIN-6 trial for semaglutide, demonstrated reductions in cardiovascular death, nonfatal myocardial infarction, and stroke. The gene discussed is GLP1R; the disease is myocardial infarction.